Deep Apple Therapeutics
United States
- San Francisco Bay Area
- 18/12/2023
- Series A
- $52,000,000
In a vast, unexplored virtual chemical space, Deep Apple Therapeutics moves with unprecedented speed to discover novel small molecules for high-value targets. Deep Apple combines ensemble cryo-EM to explore receptor conformations; deep learning; and the docking of multi-billion compound libraries generated using the company's proprietary Orchard.ai™ algorithm. Deep Apple's deep learning discovery engine is built upon founder expertise in computational modeling, protein and target structure determination, large-scale molecular docking, and the elucidation of protein dynamics and conformational transitions. This structure-based, machine-learning driven drug design approach enables the company to rapidly advance novel candidates addressing well-validated targets in inflammatory, metabolic, and endocrine diseases. For more information, visit deepappletx.com.
- Industry Biotechnology Research
- Website https://deepappletx.com/
- LinkedIn https://www.linkedin.com/company/deep-apple-therapeutics/about/
Leona Health | $14,000,000 | (Dec 18, 2025)
Limenet | $8,217,860 | (Dec 18, 2025)
Codoxo | $35,000,000 | (Dec 18, 2025)
Drive Health | $15,000,000 | (Dec 18, 2025)
DataLane | $22,500,000 | (Dec 18, 2025)
Addition Therapeutics | $100,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)
Scylos | $3,000,000 | (Dec 18, 2025)
Last Energy | $100,000,000 | (Dec 18, 2025)
Navier AI | $6,500,000 | (Dec 17, 2025)
Verisoul | $8,800,000 | (Dec 17, 2025)
Aeovian Pharmaceuticals | $55,000,000 | (Dec 17, 2025)